Shorter Post-Mastectomy Radiation Regimen Shows Non-Inferior Outcomes for Women Undergoing Breast Reconstruction

Radiation therapy after mastectomy has traditionally been delivered in a five- to six-week schedule (25 fractions). A shorter, higher-dose schedule—already standard for lumpectomy patients—had not been widely offered to women planning immediate or delayed breast reconstruction because of concerns that intensified radiation might increase reconstruction complications.

HealthDayPhase III RT CHARM Trial Supports Shorter Postmastectomy Radiation Therapy After Breast Reconstruction

The phase III RT CHARM trial (Alliance A221505) enrolled 898 women with unilateral invasive breast cancer who had undergone mastectomy and were planning or undergoing reconstruction. Recruitment occurred at 209 academic and community sites across the United States and Canada between February 2018 and August 2021. Participants were randomized 1:1 to receive either hypofractionated radiation (42.56 Gy in 16 fractions over ~3 weeks) or conventional radiation (50 Gy in 25 fractions over ~5 weeks). Randomization was stratified by reconstruction timing (immediate vs. delayed) and type (autologous vs. implant-only). The primary endpoint was the 24-month reconstruction complication rate, a composite of unplanned readmission, reoperation, severe capsular contracture, and reconstruction failure. Secondary endpoints included locoregional recurrence and acute/late radiation-related toxicity.

Phase III RT CHARM Trial Supports Shorter Postmastectomy Radiation Therapy After Breast Reconstruction HealthDay

• Reconstruction complications: At a median follow-up of 3.9 years, the 24-month complication rate was 12.3 % (52/422) with hypofractionated therapy versus 10.2 % (41/403) with conventional therapy. The estimated difference (conventional – hypofractionated) was –2.1 percentage points (95 % CI = –6.5 to 2.2), meeting the prespecified non-inferiority margin of 10 % (P = .0001).

Phase III RT CHARM Trial Supports Shorter Postmastectomy Radiation Therapy After Breast Reconstruction

• Complications among those completing reconstruction within 18 months: 12.6 % (hypofractionated) vs. 10.4 % (conventional) (P = .001 for non-inferiority).

Phase III RT CHARM Trial Supports Shorter Postmastectomy Radiation Therapy After Breast Reconstruction

• Locoregional recurrence-free survival: 97.0 % with hypofractionated therapy vs. 96.2 % with conventional therapy (hazard ratio = 1.01; 95 % CI = 0.53–1.96; P = .97). Cumulative recurrence rates were 1.5 % vs. 2.2 %, respectively.

Phase III RT CHARM Trial Supports Shorter Postmastectomy Radiation Therapy After Breast Reconstruction

• Acute toxicity: Grade 3 or higher acute toxicity occurred in 5.0 % (hypofractionated) vs. 7.7 % (conventional) (P = .11). Grade 2 dermatitis was less frequent with the shorter schedule (20 % vs. 42 %; P < .0001), as was grade 3 dermatitis (1 % vs. 3 %; P = .048). Late toxicity rates did not differ significantly.

Phase III RT CHARM Trial Supports Shorter Postmastectomy Radiation Therapy After Breast Reconstruction

These results align with earlier health-day reporting that a three-week radiation schedule produced recurrence rates of 1.5 % versus 2.2 % for the standard five-week regimen and similar reconstruction complication rates (?12 % vs. 10 %).

HealthDay

The trial provides robust evidence that a 16-fraction hypofractionated regimen is safe and non-inferior to conventional radiation for women undergoing breast reconstruction. Shortening treatment time can reduce patients’ time away from work, lower financial burden, and potentially improve quality of life without compromising oncologic control or cosmetic outcomes. The findings also suggest comparable acute skin toxicity and no increase in late adverse effects, supporting broader adoption of the shorter schedule in multidisciplinary breast-cancer care.

HealthDay

Lead researcher Dr.

HealthDay

• “Patients undergoing mastectomy and reconstruction already face a challenging medical journey,” — Dr. Matthew Poppe, lead researcher

HealthDay

The investigators suggest that clinical guidelines may be updated to incorporate hypofractionated post-mastectomy radiation as a standard option for reconstruction patients, though formal guideline revisions were not detailed in the sources.

HealthDay